title: [Construction and identification of HSV-1 vector vaccine carrying HIV-1 antigen].
abstract: To construct an HSV-1 vector vaccine carrying HIV-1 antigens, HIV-1 gp160, gag, protease and the expression elements were chained together, and then inserted into the internal inverted repeat sequence region of HSV-1 by bacterial artificial chromosome technology. Firstly, HIV-1 gp160 (including type B and C), gag and protease genes were cloned into pcDNA3 in series to generate the pcDNA/gBgp and pcDNA/gCgp, then the recombinant plasmids were transfected into 293FT cells, and HIV-1 antigen was detected from transfected cells by Western blotting. Then the expression cassettes from pcDNA/gBgp and pcDNA/gCgp, comprising HIV-1 antigen genes and expression elements, were cloned into pKO5/BN to generate the shuttle plasmids pKO5/BN/gBgp and pKO5/BN/gCgp. The shuttle plasmids were electroporated into E. coli cells that harbor an HSV-BAC, the recombinant bacteria were screened, and the recombinant DNA was extracted and transfected into Vero cells. The recombinant virus was purified through picking plaques, the virus' DNAs were identified by Southern blotting; HIV-1 antigen was detected from the recombinant HSV-1 infected cells by Western blotting, and the virus' replication competent was analyzed. As the results, gp160 and gag proteins were detected from 293FT cells transfected with pcDNA/gBgp and pcDNA/gCgp by Western blotting. The recombinant bacteria were generated from the E. coli electroporated with pKO5/BN/gBgp or pKO5/BN/gCgp. The recombinant HSV was purified from the Vero cells transfected with the recombinant DNA, the unique DNA fragment was detected from the genome of recombination HSV by Southern blotting; gp120 and gp41 were detected from the infected cells by Western blotting, and the recombinant HSV retained replication competent in mammalian cells. The results indicate that the recombinant HSV carrying HIV-1 gp160, gag and protease genes was generated, the virus retains replication competent in mammalian cells, and could be used as a replicated viral vector vaccine.
authors.forename: Xiaofei
authors.initials: X
authors.lastname: Zhao
authors.forename: Jingxia
authors.initials: J
authors.lastname: Guo
authors.forename: Xiaojuan
authors.initials: X
authors.lastname: Liu
authors.forename: Zhenghai
authors.initials: Z
authors.lastname: Ma
mesh_terms: D000818:Animals; D002522:Chlorocebus aethiops; D022202:Chromosomes, Artificial, Bacterial; D004274:DNA, Recombinant / Q000235:genetics; D004279:DNA, Viral / Q000235:genetics; D004926:Escherichia coli; D015488:HIV Antigens / Q000235:genetics / Q000276:immunology*; D019302:HIV Envelope Protein gp160 / Q000235:genetics / Q000276:immunology; D016333:HIV Protease / Q000235:genetics / Q000276:immunology; D022301:Herpes Simplex Virus Vaccines / Q000276:immunology*; D018259:Herpesvirus 1, Human / Q000502:physiology; D010957:Plasmids; D014162:Transfection; D014709:Vero Cells; D014779:Virus Replication; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000276:immunology
chemical_list: D004274:DNA, Recombinant; D004279:DNA, Viral; D015488:HIV Antigens; D019302:HIV Envelope Protein gp160; D022301:Herpes Simplex Virus Vaccines; D054301:gag Gene Products, Human Immunodeficiency Virus; C514797:gp160 protein, Human immunodeficiency virus 1; D016333:HIV Protease